Hwa An Announces Signing of Collaborative Development Agreement with Taiwan Tanabe Seiyaku Co., Ltd., Subsidiary of Tanabe Mitsubishi Pharma

1. Date of Event: August 6, 2026 2. Counterparty to the Contract or Commitment: Taiwan Tanabe Seiyaku Co., Ltd. 3. Relationship with the Company: None 4. Contract or Commitment Period (or Termination Date): August 6, 2026 – November 30, 2028 5. Main Content (Not applicable for termination): Hwa An has signed a collaborative development agreement with Taiwan Tanabe Seiyaku Co., Ltd. (hereinafter referred to as 'Tanabe Seiyaku') to jointly develop ENERGI-F703DFU for the treatment of diabetic foot ulcers. Hwa An will provide technical documentation to Tanabe Seiyaku to facilitate technology transfer. 6. Restrictive Clauses (Not applicable for termination): As stipulated in the contract. 7. Commitment Items (Not applicable for termination): As stipulated in the contract. 8. Other Important Agreements (Not applicable for termination): As stipulated in the contract. 9. Impact on the Company's Financial and Business Operations: According to the terms of the collaborative development agreement and mutual agreement between the parties, the financial value of the contract will not be disclosed. However, related amounts will be recognized and disclosed in future financial reports as required. 10. Specific Purpose: The collaboration is expected to accelerate the commercialization and sales of F703DFU in Taiwan following regulatory approval. 11. Other Matters to be Disclosed (If the subject is a publicly listed company or above, this constitutes material information under Article 7, Paragraph 8 of the Enforcement Rules of the Securities and Exchange Act): New drug development involves long timelines, high investment costs, and no guarantee of success, which may pose risks to investors. Investors are advised to carefully assess and make prudent investment decisions.